MH1 Fab' fragment of a monoclonal antibody targeted to fibrin in clots and labeled with technetium-99m: Completed a Phase I trial and beginning Phase I/II trial

American Biogenetic Sciences Inc.

Read the full 46 word article

How to gain access

Continue reading with a
two-week free trial.